Anzeige
Mehr »
Login
Montag, 27.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
US-Präsident setzt auf die Solana Blockchain! Diese Krypto-Perle profitiert enorm!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0HF9Y | ISIN: GB00B0H2K534 | Ticker-Symbol: P2F
Tradegate
23.01.25
10:46 Uhr
0,095 Euro
-0,004
-4,15 %
Branche
Öl/Gas
Aktienmarkt
Sonstige
1-Jahres-Chart
PETROFAC LIMITED Chart 1 Jahr
5-Tage-Chart
PETROFAC LIMITED 5-Tage-Chart
RealtimeGeldBriefZeit
0,0920,10826.01.
0,0980,09924.01.
Dow Jones News
287 Leser
Artikel bewerten:
(1)

Petrofac Limited: Update on financial restructuring

Finanznachrichten News

DJ Petrofac Limited: Update on financial restructuring

Petrofac Limited ( PFC) 
Petrofac Limited: Update on financial restructuring 
23-Jan-2025 / 16:09 GMT/BST 
=---------------------------------------------------------------------------------------------------------------------- 
23 January 2025 
 
UPDATE ON FINANCIAL RESTRUCTURING 
Further to its announcement on 22 December detailing that the Group had entered into a binding Lock-Up agreement with 
certain key stakeholders on a comprehensive financial restructuring plan, the Company continues to make good progress 
with the inter-conditional terms of the transaction. The following updates are provided: 
 
 1. The Consent Solicitation to amend the agreement governing the Notes, has received significant support 
  well in excess of the 50% required, with c.85% of Bondholders supporting. The consent solicitation is a key element 
  of the restructuring, and it is therefore expected that Bondholders who have consented to the change in governing 
  law will support the restructuring. 
 2. More than 70% of Bondholders have now committed to support the restructuring plan by acceding to the 
  Lock-Up agreement. This represents an increase of c. 13% since the launch of the restructuring and constitutes over 
  half of the secured creditor class. Discussions with other secured creditors continue, with the company expecting 
  further accessions in the coming weeks. 
 3. The Group has successfully reached a settlement agreement, effective on restructuring, in relation to a 
  key historical claim detailed in its 22 December announcement. Work to compromise or settle other historical and 
  actual claims continues in line with the restructuring plan. 
 4. In order to allow time to satisfy a remaining condition precedent of the Lock-Up Agreement, the Group 
  has, in consultation with key creditors and clients, adjusted the restructuring timetable by four weeks, as 
  follows: Convening Hearing - 25 February 2025; Sanction Hearing - 26 March 2025; Restructuring Effective Date - on 
  or around 31 March 2025. 
The Company will continue to update stakeholders as appropriate in line with its disclosure obligations, including 
provision of dates for the forthcoming Prospectus release, General and Creditor Meetings. 
ENDS 
For further information contact: 
Petrofac Limited 
+44 (0) 207 811 4900 
Lynette Otiti, Senior Manager, Investor Relations 
Lynette.otiti@petrofac.com 
Sophie Reid, Group Director of Communications 
Sophie.reid@petrofac.com 
Teneo (for Petrofac) 
+44 (0) 207 353 4200 
petrofac@teneo.com 
NOTES TO EDITORS 
Petrofac 
Petrofac is a leading international service provider to the energy industry, with a diverse client portfolio including 
many of the world's leading energy companies. 
Petrofac designs, builds, manages and maintains oil, gas, refining, petrochemicals and renewable energy infrastructure. 
Our purpose is to enable our clients to meet the world's evolving energy needs. Our four values - driven, agile, 
respectful and open - are at the heart of everything we do. 
Petrofac's core markets are in the Middle East and North Africa (MENA) region and the UK North Sea, where we have built 
a long and successful track record of safe, reliable and innovative execution, underpinned by a cost effective and 
local delivery model with a strong focus on in-country value. We operate in several other significant markets, 
including India, South East Asia and the United States. We have 8,000 employees based across 31 offices globally. 
Petrofac is quoted on the London Stock Exchange (symbol: PFC). 
For additional information, please refer to the Petrofac website at www.petrofac.com 
 
=---------------------------------------------------------------------------------------------------------------------- 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
ISIN:      GB00B0H2K534 
Category Code: MSCM 
TIDM:      PFC 
LEI Code:    2138004624W8CKCSJ177 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:  372474 
EQS News ID:  2073817 
 
End of Announcement EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=2073817&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face

(END) Dow Jones Newswires

January 23, 2025 11:10 ET (16:10 GMT)

© 2025 Dow Jones News
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.